Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5986706 | 0.89 | — | — | |
| SCHEMBL13107171 | 0.82 | TSHR (0.46) | EPHX2SMN1; SMN2TSHRGBA1ALDH1A1 | |
| SCHEMBL5987408 | 0.81 | — | — | |
| SCHEMBL849072 | 0.80 | PPP5C (0.42) | EPHX2PPP5CALDH1A1NAAALIPC | |
| Ethylene Glycol SCHEMBL27905327 | 0.80 | TSHR (0.50) | EPHX2SMN1; SMN2TSHRPPP5CGBA1 | |
| SCHEMBL19576089 | 0.80 | SMN1; SMN2 (0.38) | EPHX2SMN1; SMN2TSHRPPP5CGBA1 | |
| SCHEMBL13106449 | 0.80 | MEN1 (0.45) | EPHX2SMN1; SMN2TSHRGBA1ALDH1A1 | |
| SCHEMBL13401898 | 0.80 | SMN1; SMN2 (0.38) | EPHX2SMN1; SMN2TSHRPPP5CGBA1 | |
| SCHEMBL16769995 | 0.80 | PPP5C (0.37) | EPHX2SMN1; SMN2TSHRPPP5CGBA1 | |
| SCHEMBL2606649 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340636-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF AUTOPHAGY | UNIV TEXAS (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340636-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF AUTOPHAGY | ATG7, BECN1, ULK1 | EPHX2 3220/4885SMN1; SMN2 4541/4885TSHR 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.